Cryoport (CYRX) Q2 2026 earnings review
Profitability Milestone Achieved, But Growth Engines Stall
Cryoport achieved a significant milestone in Q2 2026, posting positive Adjusted EBITDA ($0.4M) and reversing a multi-year trend of operating losses. This occurred ahead of management's previously stated H2 2026 target. However, the top-line narrative is concerning: total revenue growth sharply decelerated to 8% YoY from 16% in Q1. This was driven by a complete stall in the Life Sciences Products segment (0% YoY growth) and a severe deceleration in Commercial Cell and Gene Therapy (CGT) support revenue, which grew just 9% YoY compared to 26% in the prior quarter. While BioStorage services (+25% YoY) and the expanding clinical pipeline remain robust, the sudden slowdown in key growth vectors raises near-term demand questions.
🐂 Bull Case
Management previously targeted H2 2026 for positive Adjusted EBITDA. Achieving $0.4M in Q2 proves their 'pathway to profitability' initiatives are yielding tangible operating leverage earlier than expected.
The company now supports a record 779 clinical trials (up from 728 a year ago), with 94 in Phase 3. Recent approvals (Orca Bio's TREGZI and a label expansion for Vertex's CASGEVY) validate the pipeline's conversion potential.
🐻 Bear Case
Commercial CGT revenue is supposed to be the company's primary growth engine. Its growth abruptly decelerated from 26% YoY in Q1 to just 9% YoY in Q2, calling into question the pace of market adoption for approved therapies.
Life Sciences Products revenue flatlined at $21.0M (0% YoY growth), a sharp reversal from 15% growth in Q1. Margins in this segment also compressed by 270 basis points YoY.
⚖️ Verdict: ⚪
Neutral. The early pivot to positive Adjusted EBITDA is a massive operational win, but the sudden and severe top-line deceleration in both the Products division and Commercial CGT segment makes it difficult to justify an aggressive growth multiple in the near term.
Key Themes
Commercial CGT Growth Decelerating Rapidly
Management has repeatedly cited Commercial CGT support as the dominant future revenue factor. However, Q2 Commercial CGT revenue grew only 9% YoY to $9.4 million. This is a dramatic deceleration from Q1's 26% growth and Q4 2025's 29% growth. If expanding patient populations in community settings are truly ramping as management claims, this revenue stream should be accelerating, not falling into single digits.
Life Sciences Products Reversing to Flat
After signaling a return to 'high single-digit growth' in Q1 with a 15% YoY print, the Life Sciences Products segment (MVE) completely stalled in Q2, generating $21.0M (0% YoY). Adding pressure, the segment's gross margin fell to 42.2% from 44.9% a year ago. This suggests that the post-COVID destocking recovery may have been a temporary blip rather than a sustained structural rebound.
BioStorage and BioServices Outperformance
The brightest spot on the top line was BioStorage/BioServices, which generated 25% YoY growth to reach $5.6M. This validates the company's integrated platform strategy—customers are utilizing Cryoport for broader supply chain needs beyond simple transit, supporting the higher overall Services gross margin (49.9%).
Clinical Pipeline Maturation Accelerating
Cryoport added 51 net new trials YoY, bringing the total to 779. More importantly, the late-stage funnel continues to swell: Phase 3 trials increased from 82 to 94 YoY. The recent FDA approval of Orca Bio's TREGZI and label expansion for Vertex's CASGEVY highlight the steady conversion of this clinical pipeline into commercial revenue streams.
Global Supply Chain Infrastructure Launch Imminent
Management confirmed that both the Paris, France and Santa Ana, California Global Supply Chain Centers remain on track to open in Q4 2026. While these will carry upfront startup costs, they are critical for securing EMEA footprint expansion and long-term margin leverage heading into 2027.
Other KPIs
Reversing. Achieved positive Adjusted EBITDA ahead of the H2 2026 timeline provided in prior quarters. This represents a $1.3 million YoY improvement from negative $0.9 million in Q2 2025, proving the company can extract operating leverage even in a quarter where total top-line growth decelerated to 8%.
Stable to slightly declining. Down from 47.0% in Q2 2025. This was a tale of two segments: Services gross margin expanded 100 bps to 49.9%, while Products gross margin compressed 270 bps to 42.2%.
Remains highly liquid, providing a massive buffer to fund the Q4 2026 facility launches in Paris and Santa Ana without requiring external capital. Cash is down slightly from $403.6 million in Q1 2026, primarily reflecting ongoing capital expenditures.
Guidance
Management confirmed that both the Paris BioServices operations and the Santa Ana Global Supply Chain Center are scheduled to launch in Q4 2026. Note: The press release notably lacked any reaffirmation of the $192-$196M FY26 revenue guidance given in Q1, an omission that requires clarification on the earnings call.
Key Questions
Commercial CGT Deceleration
Commercial CGT revenue growth plummeted from 26% in Q1 to 9% in Q2. Is this due to delayed adoption of specific therapies, a reduction in patient volumes, or increased competitive pressures in the community care setting?
Products Segment Stalling
After stating in Q1 that the Life Sciences Products market was 'solidifying' for high single-digit growth, Q2 revenue was flat year-over-year. What specifically caused this stall, and how much visibility do you have into H2 capital equipment orders?
FY26 Revenue Guidance
The press release omitted a specific update to the $192M-$196M full-year revenue guidance issued in Q1. Given the 8% growth in Q2, are you maintaining this range, which would imply a required re-acceleration in the second half of the year?
Margin Impact of Upcoming Facility Launches
With the Paris and Santa Ana facilities opening in Q4, how much margin drag should we model for the startup phase, and will this threaten your newly achieved positive Adjusted EBITDA status?